跳至主要内容
临床试验/NCT03700047
NCT03700047已完成不适用

A Randomized, Evaluator-Blinded, Parallel, Comparator-Controlled Study to Evaluate the Safety and Effectiveness of GAL1704 for Cheek Augmentation and Correction of Midface Contour Deficiencies

Galderma R&D18 个研究点 分布在 1 个国家目标入组 270 人开始时间: 2018年10月18日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
Galderma R&D
入组人数
270
试验地点
18
主要终点
Assess Efficacy of Study Treatment Using Medicis Midface Volume Score (MMVS)

研究概览

简要总结

An interventional study to evaluate the safety and effectiveness of GAL1704 for cheek augmentation and the correction of midface volume deficiencies by demonstrating non-inferiority in change from baseline, relative to an active comparator.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Outcomes Assessor)

入排标准

年龄范围
22 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Subjects assessed at baseline by the Blinded Evaluator as Grade 2, 3, or 4 on the MMVS on each side of the midface.

排除标准

  • Previous use of any HA based or collagen based biodegradable tissue augmentation therapy within 12 months prior to the baseline visit

结局指标

主要结局

Assess Efficacy of Study Treatment Using Medicis Midface Volume Score (MMVS)

时间窗: 12 weeks

Change in midface fullness from Baseline to 12 weeks using the Medicis Midface Volume Score (MMVS), where a decreasing score correlates with increasing midface fullness, namely a score of 1 being the most full and a score of 4 being the least full.

次要结局

未报告次要终点

研究者

发起方
Galderma R&D
申办方类型
Industry
责任方
Sponsor

研究点 (18)

Loading locations...

相似试验